Skip to content
Boca Raton City Online – Lifestyle
Author:
Charm Therapeutics
CHARM Therapeutics and Collaborator Dr. Florian Perner to Present Compelling Data Showing the Potential of Next-Generation Menin Inhibitors to Deliver More Durable Responses for AML at the 8th ASH Annual Meeting
November 11, 2026
CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia
October 7, 2026
CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor
August 18, 2026